Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ENMD 2076

Drug Profile

ENMD 2076

Alternative Names: ENMD-2076; ENMD-981693; MKC-1693

Latest Information Update: 11 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Miikana Therapeutics
  • Developer CASI Pharmaceuticals
  • Class Antineoplastics; Piperazines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Aurora kinase A inhibitors; Fms-like tyrosine kinase 3 inhibitors; Type 3 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Multiple myeloma; Liver cancer; Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cancer; Haematological malignancies; Liver cancer; Multiple myeloma; Ovarian cancer; Soft tissue sarcoma; Triple negative breast cancer

Most Recent Events

  • 16 Mar 2020 ENMD 2076 is available for licensing as of 16 Mar 2020. https://www.casipharmaceuticals.com/
  • 16 Mar 2020 Discontinued - Phase-I for Cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 16 Mar 2020 Discontinued - Phase-II for Liver cancer (Late-stage disease) in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top